Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2013 Jan;10(1):10-1. doi: 10.1038/nrclinonc.2012.197. Epub 2012 Nov 13.

Ziv-aflibercept: binding to more than VEGF-A--does more matter?

Author information

1
Duke University Medical Center, Box 3182, 2301 Erwin Road, Durham, NC 27710, USA.

Abstract

The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in non-small-cell lung cancer. Thus, VEGF-directed agents might be useful throughout the continuum of care in mCRC, but biomarkers are needed to identify patients likely to benefit.

PMID:
23149898
DOI:
10.1038/nrclinonc.2012.197
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center